AMPA glutamate receptors mediate the antidepressant-like effects of N-acetylcysteine in the mouse tail suspension test

Behavioural Pharmacology

Volumn 23, Issue 2, 2012, Pages 171-177

  Linck, Viviane M ^a,b   Costa Campos, Luciane ^a,c   Pilz, Luísa K ^a   Garcia, Cícero R L ^a,c   Elisabetsky, Elaine ^a,b,c  

^a Ethnopharmacology Laboratory   (Brazil)

^b Department of Biological Sciences   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

a amino acid 3 hydroxy 5 methyl 4 isoxazol propionic acid; antidepressants; mouse; N acetylcysteine; noradrenaline; serotonin; tail suspension test

Indexed keywords

2,3 DIHYDROXY 6 NITRO 7 SULFAMOYL BENZO[F]QUINOXALINE 2,3 DIONE; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ACETYLCYSTEINE; ADRENERGIC RECEPTOR AFFECTING AGENT; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; DESIPRAMINE; DXETRO ALPHA METHYL Q TYROSINE; ESCITALOPRAM; FENCLONINE METHYL ESTER; FLUOXETINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; IMIPRAMINE; N METHYL DEXTRO ASPARTIC ACID; NORADRENALIN; Q CHLOROPHENYLALANINE METHYL ESTER HYDROCHLORIDE; SEROTONIN; SEROTONIN RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BAGG ALBINO MOUSE; CONTROLLED STUDY; MALE; MOUSE; NONHUMAN; PREDICTIVE VALUE; PSYCHOLOGIC TEST; TAIL SUSPENSION TEST;

ACETYLCYSTEINE; ALPHA-METHYLTYROSINE; ANIMALS; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; FENCLONINE; HINDLIMB SUSPENSION; LOCOMOTION; MALE; MICE; MICE, INBRED STRAINS; N-METHYLASPARTATE; QUINOXALINES; RECEPTORS, AMPA;

EID: 84858707669     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0b013e3283512c3a     Document Type: Article

References (67)

1. Abdel-Wahab BA, Salama RH (2011). Venlafaxine protects against stressinduced oxidative DNA damage in hippocampus during antidepressant testing in mice. Pharmacol Biochem Behav 100:59-65.
2. Alt A, Nisenbaum ES, Bleakman D, Witkin JM (2006a). A role for AMPA receptors in mood disorders. Biochem Pharmacol 71:1273-1288.
3. Alt A, Weiss B, Ogden AM, Li X, Gleason SD, Calligaro DO, et al. (2006b). In vitro and in vivo studies in rats with LY293558 suggest AMPA/kainate receptor blockade as a novel potential mechanism for the therapeutic treatment of anxiety disorders. Psychopharmacology (Berl) 185:240-247. (Pubitemid 43363620)
4. Ampuero E, Rubio F, Falcon R, Sandoval M, Diaz-Veliz G, Gonzalez R, et al. (2010). Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 169:98-108.
5. Bai F, Li X, Clay M, Lindstrom T, Skolnick P (2001). Intra-and interstrain differences in models of "behavioral despair". Pharmacol Biochem Behav 70:187-192. (Pubitemid 33049928)
6. Baker D, McFarland K, Lake R, Shen H, Toda S, Kalivas P (2003). N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci 1003:349-351. (Pubitemid 38083068)
7. Barbon A, Caracciolo L, Orlandi C, Musazzi L, Mallei A, La Via L, et al. (2011). Chronic antidepressant treatments induce a time-dependent up-regulation of AMPA receptor subunit protein levels. Neurochem Int 59:896-905.
8. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. (2008a). N-acetyl cysteine for depressive symptoms in bipolar disorder-a double-blind randomized placebo-controlled trial. Biol Psychiatry 64:468-475.
9. Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, et al. (2008b). N-acetyl cysteine as a glutathione precursor for schizophrenia-a doubleblind, randomized, placebo-controlled trial. Biol Psychiatry 64:361-368.
10. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, et al. (2011). The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 135 (1-3):389-394.
11. Borgström L, Ka°gedal B, Paulsen O (1986). Pharmacokinetics of N-acetylcysteine in man. Eur J Clin Pharmacol 31:217-222. (Pubitemid 17014593)
12. Cartmell J, Schoepp DD (2000). Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75:889-907. (Pubitemid 30660476)
13. Chen H, Stoker A, Markou A (2010). The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice. Psychopharmacology (Berl) 209: 343-350.
14. Cryan JF, Mombereau C, Vassout A (2005). The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29 (4-5):571-625. (Pubitemid 40755457)
15. Cumurcu BE, Ozyurt H, Etikan I, Demir S, Karlidag R (2009). Total antioxidant capacity and total oxidant status in patients with major depression: impact of antidepressant treatment. Psychiatry Clin Neurosci 63:639-645.
16. Dean O, Giorlando F, Berk M (2011). N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci 36:78-86.
17. Dodd S, Dean O, Copolov D, Malhi G, Berk M (2008). N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility. Expert Opin Biol Ther 8:1955-1962.
18. Du J, Suzuki K, Wei Y, Wang Y, Blumenthal R, Chen Z, et al. (2007). The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32:793-802. (Pubitemid 46426179)
19. Dupuy JM, Ostacher MJ, Huffman J, Perlis RH, Nierenberg AA (2011). A critical review of pharmacotherapy for major depressive disorder. Int J Neuropsychopharmacol 14:1-15.
20. Elisabetsky E (2007). Phytotherapy and the new paradigm of drugs mode of action. Revista Productos Naturales XII:459-464.
21. Farley S, Apazoglou K, Witkin JM, Giros B, Tzavara ET (2010). Antidepressant-like effects of an AMPA receptor potentiator under a chronic mild stress paradigm. Int J Neuropsychopharmacol 13:1207-1218.
22. Ferreira F, Biojone C, Joca S, Guimarães F (2008). Antidepressant-like effects of N-acetyl-L-cysteine in rats. Behav Pharmacol 19:747-750.
23. Gorman JM (2006). Gender differences in depression and response to psychotropic medication. Gend Med 3:93-109. (Pubitemid 44057819)
24. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS (2005). Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 143:415-426. (Pubitemid 41341413)
25. Hashimoto K (2009). Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61:105-123.
26. Hashimoto K (2010). The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 15:1558-1568.
27. Kessler RC, Wang PS (2008). The descriptive epidemiology of commonly occurring mental disorders in the United States. Annu Rev Public Health 29:115-129. (Pubitemid 351600402)
28. Koe BK, Weissman A (1966). p-Chlorophenylalanine: a specific depletor of brain serotonin. J Pharmacol Exp Ther 154:499-516.
29. Labonte B, Bambico FR, Gobbi G (2009). Potentiation of excitatory serotonergic responses by MK-801 in the medial prefrontal cortex. Naunyn Schmiedebergs Arch Pharmacol 380:383-397.
30. Lavoie S, Murray MM, Deppen P, Knyazeva MG, Berk M, Boulat O, et al. (2008). Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients. Neuropsychopharmacology 33:2187-2199. (Pubitemid 351992093)
31. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, et al. (2011). Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69: 754-761.
32. Linck VM, da Silva AL, FigueiróM, Piato AL, Herrmann AP, Dupont Birck F, et al. (2009). Inhaled linalool-induced sedation in mice. Phytomedicine 16: 303-307.
33. Little A (2009). Treatment-resistant depression. Am Fam Physician 80:167-172.
34. Lobato KR, Cardoso CC, BinfaréRW, Budni J, Wagner CL, Brocardo PS, et al. (2010). Alpha-tocopherol administration produces an antidepressant-like effect in predictive animal models of depression. Behav Brain Res 209: 249-259.
35. Machado-Vieira R, Salvadore G, DiazGranados N, Zarate CA Jr (2009). Ketamine and the next generation of antidepressants with a rapid onset of action. Pharmacol Ther 123:143-150.
36. Maeng S, Zarate CA, Du J, Schloesser RJ, McCammon J, Chen G, et al. (2008). Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352. (Pubitemid 351146651)
37. Maes M, Galecki P, Chang YS, Berk M (2011). A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuropsychopharmacol Biol Psychiatry 35:676-692.
38. Magalhães P, Dean O, Bush A, Copolov D, Malhi G, Kohlmann K, et al. (2010). N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord 129 (1-3):317-320.
39. Mantovani M, Pértile R, Calixto JB, Santos AR, Rodrigues AL (2003). Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-D-aspartate receptors and the Larginine-nitric oxide pathway. Neurosci Lett 343:1-4. (Pubitemid 36577198)
40. Martínez M, Martínez N, Hernández A, Ferrándiz M (1999). Hypothesis: can N-acetylcysteine be beneficial in Parkinson's disease? Life Sci 64: 1253-1257.
41. Michael-Titus A, Bains S, Jeetle J, Whelpton R (2000). Imipramine and phenelzine decrease glutamate overflow in the prefrontal cortex-a possible mechanism of neuroprotection in major depression? Neuroscience 100:681-684.
42. Mitchell ND, Baker GB (2010). An update on the role of glutamate in the pathophysiology of depression. Acta Psychiatr Scand 122:192-210.
43. O'Leary OF, Bechtholt AJ, Crowley JJ, Hill TE, Page ME, Lucki I (2007). Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugsin the mouse tail suspension test. Psychopharmacology (Berl) 192:357-371. (Pubitemid 46701581)
44. Ostroff R, Gonzales M, Sanacora G (2005). Antidepressant effect of ketamine during ECT. Am J Psychiatry 162:1385-1386.
45. Papakostas GI, Petersen T, Denninger JW, Montoya HD, Nierenberg AA, Alpert JE, et al. (2003). Treatment-related adverse events and outcome in a clinical trial of fluoxetine for major depressive disorder. Ann Clin Psychiatry 15 (3-4):187-192. (Pubitemid 38176338)
46. Piato A, Rizon L, Martins B, Nunes D, Elisabetsky E (2009). Antidepressant profile of Ptychopetalum olacoides Bentham (Marapuama) in mice. Phytother Res 23:519-524.
47. Pilc A, Chaki S, Nowak G, Witkin JM (2008). Mood disorders: regulation by metabotropic glutamate receptors. Biochem Pharmacol 75: 997-1006.
48. Poleszak E, WlaźP, Kedzierska E, Nieoczym D, Wróbel A, Fidecka S, et al. (2007a). NMDA/glutamate mechanism of antidepressant-like action of magnesium in forced swim test in mice. Pharmacol Biochem Behav 88:158-164. (Pubitemid 350115999)
49. Poleszak E, WlaźP, Wróbel A, Dybała M, Sowa M, Fidecka S, et al. (2007b). Activation of the NMDA/glutamate receptor complex antagonizes the NMDA antagonist-induced antidepressant-like effects in the forced swim test. Pharmacol Rep 59:595-600.
50. Pomierny-Chamioło L, Poleszak E, Pilc A, Nowak G (2010). NMDA but not AMPA glutamatergic receptors are involved in the antidepressant-like activity of MTEP during the forced swim test in mice. Pharmacol Rep 62:1186-1190.
51. Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW (2008). An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101, 606, in patients with treatment-refractory major depressive disorder. J Clin Psychopharmacol 28:631-637.
52. Reis de Oliveria I, Diquet B, Van der Meersch V, Dardennes R, Gonidec J, do Prado-Lima PA (1990). Self-inhibiting action of nortriptyline's anti-immobility effect at high plasma and brain levels in mice. Psychopharmacology (Berl) 102:553-556. (Pubitemid 20379515)
53. Rojas-Corrales M, Gibert-Rahola J, MicóJ (1998). Tramadol induces antidepressant-type effects in mice. Life Sci 63:PL175-PL180. (Pubitemid 29369111)
54. Roth BL, Sheffler DJ, Kroeze WK (2004). Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3:353-359. (Pubitemid 38499762)
55. Sanacora G, Zarate C, Krystal J, Manji H (2008). Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov 7:426-437. (Pubitemid 351619114)
56. Shelton RC, Osuntokun O, Heinloth AN, Corya SA (2010). Therapeutic options for treatment-resistant depression. CNS Drugs 24:131-161.
57. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl) 85:367-370. (Pubitemid 15123115)
58. Szewczyk B, Poleszak E, Sowa-Kućma M, Wróbel A, Słotwiński S, Listos J, et al. (2010). The involvement of NMDA and AMPA receptors in the mechanism of antidepressant-like action of zinc in the forced swim test. Amino Acids 39:205-217.
59. Tokarski K, Bobula B, Wabno J, Hess G (2008). Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex. Neuroscience 153:789-795.
60. Tokita K, Yamaji T, Hashimoto K (2011). Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav 100:688-704.
61. Wang R, Xu Y, Wu HL, Li YB, Li YH, Guo JB, et al. (2008). The antidepressant effects of curcumin in the forced swimming test involve 5-HT1 and 5-HT2 receptors. Eur J Pharmacol 578:43-50. (Pubitemid 350179755)
62. Wang X, Yang Y, Zhou X, Wu J, Li J, Jiang X, et al. (2011). Propofol pre-treatment increases antidepressant-like effects induced by acute administration of ketamine in rats receiving forced swimming test. Psychiatry Res 185 (1-2):248-253.
63. Willner P, Mitchell P (2003). Animal models of subtypes of depression. In: Kasper S, Boer J, editors. Handbook of depression and anxiety. New York: CRC Press.
64. Youdim MB, Buccafusco JJ (2005). Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26:27-35. (Pubitemid 40052707)
65. Zarate CJ, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D, et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry 63:856-864. (Pubitemid 44188478)
66. Zhong P, Yuen E, Yan Z (2008). Modulation of neuronal excitability by serotonin-NMDA interactions in prefrontal cortex. Mol Cell Neurosci 38:290-299.
67. Zomkowski AD, Engel D, Gabilan NH, Rodrigues AL (2010). Involvement of NMDA receptors and L-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effects of escitalopram in the forced swimming test. Eur Neuropsychopharmacol 20:793-801.